Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
- DOI
- 10.1016/j.lungcan.2024.107919
- Published
- 2024 Sep
- Container
- Lung cancer (Amsterdam, Netherlands)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2024.107919,
title = {Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.},
author = {Bauman JR and Liu G and Preeshagul I and Liu SV and Melosky B and Abrahami D and Li B and Thomaidou D and Duncan K and Krulewicz S and Rupp M and Lin JJ},
year = {2024},
journal = {Lung cancer (Amsterdam, Netherlands)},
doi = {10.1016/j.lungcan.2024.107919},
url = {https://doi.org/10.1016/j.lungcan.2024.107919}
}RIS
TY - JOUR TI - Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer. AU - Bauman JR AU - Liu G AU - Preeshagul I AU - Liu SV AU - Melosky B AU - Abrahami D AU - Li B AU - Thomaidou D AU - Duncan K AU - Krulewicz S AU - Rupp M AU - Lin JJ PY - 2024 JO - Lung cancer (Amsterdam, Netherlands) DO - 10.1016/j.lungcan.2024.107919 UR - https://doi.org/10.1016/j.lungcan.2024.107919 ER -
APA
JR, B., G, L., I, P., SV, L., B, M., D, A., B, L., D, T., K, D., S, K., M, R., & JJ, L. (2024). Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2024.107919
Source records
- pubmed · retrieved 2026-09-27T10:45:31.024Z